| Sygnia Itrix Health Innovation AMETF
Type: Active ETF |
JSE code: SYGH |
| Benchmark: Solactive Developed Markets Healthcare 150 | Classification: Global Equity |
| Tax-free investing: Allowed (What is tax-free?) | Market cap: R183 million |
| TIC (TER where TIC not indicated): 0.55000000000000004% (What is TER?) | Distribution: Semi Annual | Jul-25: 16.87887, Jan-26: 10.30382 (cents/unit) |
| Top holdings:
Eli Lilly Ord Shs (10.9%), Johnson & Johnson Ord Shs (6.3%), AbbVie Ord Shs (4.5%), UnitedHealth Group Ord Shs (4.0%), Roche PS Par Shs (3.5%), Merck & Co Ord Shs (3.4%), Astrazeneca Ord Shs (3.3%), Novartis Ord Shs (3.2%), Thermo Fisher Scientific Ord Shs (2.1%) |
|
| MDD updated: 31 May 2026 (Understanding your MDD) | |
| Description:
The fund aims to provide investors access to healthcare innovation stocks and deliver long-term capital growth |
|
All data from the issuer Minimum Disclosure Documents (MDD) and updated as they update their MDDs. Please check all data, we take no responsibility for errors.